Enoxaparin in unstable angina patients with renal failure.
about
Pentasaccharides for the treatment of deep vein thrombosisNadroparine calcium or enoxaparine in acute coronary syndrome patients suffering renal insufficiency: The nadroparin versus enoxaparin (NaVe) study designExperience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol.Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years oldAdministration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.Dosing low molecular weight heparins in kidney disease.Rectus sheath hematoma complicating low-molecular weight heparin therapy.Dosing of Enoxaparin in Renal Impairment.Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation.[Periprocedual management of vitamin K antagonist's with low molecular weight heparins during invasive procedures--Consensus of experts].Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.Life-threatening hemorrhage after dalteparin therapy in a patient with impaired renal function.Pentasaccharides for the treatment of deep vein thrombosis.Analysis of enoxaparin dose titration at a large, tertiary teaching facility.
P2860
Q24186811-03877461-08D2-4607-A101-811544002572Q24794480-975BAE13-EE2D-4402-9D64-B1B1556A79C2Q35581075-44BCDF95-01C2-41FA-A133-587770BB8ACEQ35826839-D9D9EC96-E691-46DD-BE3B-6D6EEC0B5C6BQ35827649-A4311BB0-E53B-4C00-BB6D-9104D33625A1Q35944733-B4AF88DB-E677-4E4E-950C-474A86531FBCQ36102602-23783FB3-4A47-4A14-BB30-B7195B1EC1EDQ36128828-11486F99-8F47-42AF-B5A2-E4CDE723D5A9Q36603232-6F433831-1CB2-4371-82E0-3F9AFE4B6F37Q37867276-2B8F15B5-99FE-4348-90D9-02571A29D6A9Q38432635-EB5D0BA4-3BC2-4815-BC9A-9D7E0C65F84AQ38851458-83C43B0A-7628-47D5-A18A-8FF1FD7A7AF9Q44437063-3F220BDD-2426-4124-BFA8-89E31470EF95Q44440485-3E5488B0-3BD1-426D-B847-E55942F1970AQ44557763-A15D5AC5-9259-463B-8C46-22F590D9BFD6Q44904202-5EAA74F1-9759-4005-AA68-F78D3EC99598Q46520643-B68EA378-0A93-4067-A71C-0826EAFDDA09Q47376811-3BBFEC17-DF37-4D44-BC6B-78666D156F08Q50443127-0C540B88-ED6B-4462-8D96-EA02CBEBD223
P2860
Enoxaparin in unstable angina patients with renal failure.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Enoxaparin in unstable angina patients with renal failure.
@en
Enoxaparin in unstable angina patients with renal failure.
@nl
type
label
Enoxaparin in unstable angina patients with renal failure.
@en
Enoxaparin in unstable angina patients with renal failure.
@nl
prefLabel
Enoxaparin in unstable angina patients with renal failure.
@en
Enoxaparin in unstable angina patients with renal failure.
@nl
P2093
P1476
Enoxaparin in unstable angina patients with renal failure.
@en
P2093
P356
10.1016/S0167-5273(01)00455-7
P407
P577
2001-08-01T00:00:00Z